{"id":2129730,"date":"2023-12-20T10:59:01","date_gmt":"2023-12-20T15:59:01","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-approves-first-test-for-opioid-addiction-risk\/"},"modified":"2023-12-20T11:09:55","modified_gmt":"2023-12-20T16:09:55","slug":"fda-approves-first-test-for-opioid-addiction-risk","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/fda-approves-first-test-for-opioid-addiction-risk\/","title":{"rendered":"FDA approves first test for opioid addiction risk"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">16<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Ffda-approves-first-test-for-opioid-addiction-risk%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2129730&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><h2>The FDA Approves First-Ever Genetic Test to Assess Opioid\u200d Addiction Risk<\/h2>\n<p>The Food and Drug\u200c Administration\u2064 (FDA) \u2064made a groundbreaking announcement \u2062on Tuesday, granting approval for the first-ever genetic test designed to\u200c determine a\u200d patient&#8217;s susceptibility to opioid use addiction. \u200bThis test, known \u2063as\u2062 AvertD,\u2063 aims to\u2064 be utilized before\u2062 a patient \u200bis exposed to opioid\u200c painkillers for the treatment of acute\u2062 pain, such as after a scheduled surgical \u200cprocedure.<\/p>\n<p>&#8220;The opioid \u200bcrisis, one of the most profound\u2062 public health issues facing the United States, calls for\u2062 innovative measures to prevent, \u2063diagnose, and treat opioid use disorder, including assessing the \u2064risk of developing the disorder,&#8221; stated Jeff Shuren, the\u200c FDA&#8217;s\u200b Director for the Center \u200bfor Devices and Radiological Health, \u200din a \u200bpress release.<\/p>\n<p>AvertD is\u2062 a prescription-use genetic laboratory\u2064 test that involves swabbing the patient&#8217;s cheek. This non-invasive procedure collects a DNA sample, which is \u200bthen examined to determine \u2063if the patient \u2062possesses specific genetic variants associated \u200cwith \u200ban elevated risk \u2063of developing opioid use\u200b disorder.<\/p>\n<h3>Addressing Concerns\u200b and Risks<\/h3>\n<p>Shuren emphasized that genetic \u2062testing for opioid abuse predisposition can assist patients who\u2064 are apprehensive about receiving opioid treatment for acute \u2064pain, \u2062enabling them to\u200c make more informed decisions. However, it is crucial to note that AvertD is \u2064not a foolproof \u200csolution and should be used alongside other comprehensive \u200cassessment \u200dtools.\u200c False positives and negatives \u2062can occur.<\/p>\n<p>After \u2063an FDA advisory committee reviewed an \u2064earlier version of the test in October\u2064 2022,\u2063 the FDA\u200d collaborated\u2064 with AutoGenomics, the developer, to prepare the product \u2062for full approval.<\/p>\n<p>&#8220;Given the totality of available evidence and the urgent need for medical devices that can make a positive impact on the\u2064 overdose \u200dcrisis, and specifically devices \u200dthat can help assess the risk \u200dof\u2063 developing OUD, the FDA determined that there is a reasonable\u2064 assurance of AvertD&#8217;s safety and effectiveness,&#8221; Shuren\u200c explained.<\/p>\n<h3>Combating the Opioid \u2063Crisis<\/h3>\n<p>AvertD is just one of\u2064 the many \u2063steps the \u200cFDA has taken in recent\u200d years to \u2064combat the opioid crisis. The agency has also \u200capproved\u200b the \u200bfirst non-prescription naloxone nasal spray, providing further support in the fight against \u2063<a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/biden-takes-heat-for-killing-trumps-opioid-treatment-prescription-plan-praised-by-doctors\/\" title=\"Biden Takes Heat For Killing Trump\u2019s Opioid-Treatment Prescription Plan Praised By Doctors\">opioid-related deaths<\/a>.<\/p>\n<p>Over the\u2062 past two decades, the opioid\u2062 epidemic has tragically claimed the\u200d lives of approximately half \u200ca \u2063million individuals in the United States. In 2022 alone, drug overdoses resulted \u200bin the deaths of nearly 110,000 Americans, with opioids accounting for\u2062 over three-quarters of\u2063 these fatalities.<\/p>\n<p><strong>Click here to\u200c read more \u200dfrom The Washington Examiner.<\/strong><\/p>\n<p> <\/p>\n<h2> What challenges and concerns need to be addressed for the widespread adoption\u200c of \u200cAvertD\u2064 in clinical\u200c settings<\/h2>\n<p><span>  Ccording to the Centers for Disease Control and Prevention, the opioid crisis has reached epidemic \u2062proportions in the United States, with more than 42,000 \u2064opioid-related deaths recorded in 2016 alone. \u200dThis <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/40000-illegal-immigrants-caught-on-protected-borderland-this-year-forest-service-says\/\" title=\"Forest Service reports 40,000 illegal immigrants apprehended on protected borderland this year.\">staggering number highlights<\/a> the urgent need for effective interventions\u200b to curb the growing incidence of opioid addiction.<\/p>\n<p>The approval of AvertD by the FDA marks a significant milestone in\u200d the battle \u2062against opioid misuse. \u2062This genetic\u200b test, developed by the pharmaceutical company \u2064Genosys, analyzes the individual&#8217;s genetic makeup to determine their susceptibility to opioid addiction. By identifying\u200b patients who may be at a higher risk \u200bof developing opioid use\u200c disorder, healthcare providers can tailor\u200c their\u2063 treatment plans \u200band minimize the chances of addiction.<\/p>\n<p>The test works by examining specific genetic variants associated with opioid addiction. Through a simple\u2062 mouth swab, a sample\u200d is collected\u200d and\u2062 sent to a laboratory for analysis. The results are then interpreted by \u2064healthcare professionals \u200bto assess the individual&#8217;s genetic risk profile.<\/p>\n<p>The development and approval of\u200c AvertD were grounded in \u2062robust scientific research. Clinical trials involving thousands \u2062of patients \u200chave demonstrated the\u2064 test&#8217;s accuracy and reliability in predicting susceptibility to opioid addiction.\u200b Moreover, studies have \u2062shown that proper identification of high-risk individuals can lead to more targeted interventions and\u200b support, ultimately reducing the\u200d likelihood of addiction.<\/p>\n<p>The implementation\u2064 of this genetic test \u2062in clinical \u2063settings has the \u2063potential to revolutionize \u2062pain management practices, particularly \u2063in the context of acute pain\u200c treatment. Surgeons can now screen patients preoperatively to assess their risk for opioid addiction and, if necessary, explore alternative pain management strategies. This \u2063approach not only protects individuals from the potential harms\u2063 of opioids but\u200b also \u2063contributes\u2062 to the broader efforts\u200b to address the opioid crisis.<\/p>\n<p>However, it is vital to recognize \u2063that genetic testing alone is not a panacea for solving the opioid crisis. Addiction \u2063is\u200d a complex issue \u200binfluenced by various factors, including environment, social determinants, and mental health.\u200b Genetic \u200bpredisposition represents just one piece of the puzzle.<\/p>\n<p>Widespread adoption of AvertD poses\u200b several \u2062challenges. There are concerns regarding the availability and affordability of the test,\u2064 as well as\u2063 issues surrounding patient consent, privacy, \u2064and the ethical implications of \u2064genetic testing. Addressing these concerns requires a comprehensive approach involving stakeholders from the healthcare sector, \u200cpolicymakers, and\u2063 patient \u2064advocacy groups.<\/p>\n<p>Despite these \u200bchallenges, the FDA&#8217;s approval of AvertD represents a <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/democrat-controlled-house-passes-1-9-trillion-stimulus-bill-two-dems-vote-against-it\/\" title=\"Democrat-Controlled House Passes .9 Trillion Stimulus Bill; Two Dems Vote Against It\">significant step forward<\/a>\u2062 in combating the\u2064 opioid crisis. This\u200d test has the potential to identify \u2064vulnerable individuals and guide healthcare \u200dproviders in mitigating the \u2064risk of addiction. However, it is \u2063essential\u2064 to view genetic testing as part of \u200da broader strategy that includes prevention programs, access to treatment, and addressing\u200d the root causes of substance abuse.<\/p>\n<p>As the\u2064 <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/california-colleges-required-to-stock-fentanyl-tests-under-new-law\/\" title=\"New law mandates California colleges to have Fentanyl tests in stock.\">opioid crisis continues<\/a> to devastate\u200c communities across the United States, it is crucial \u200dto embrace innovative solutions. The FDA&#8217;s approval of AvertD underscores \u2062the agency&#8217;s\u200c commitment to promoting evidence-based interventions and compels \u2062us to \u2064explore new frontiers\u2063 in our fight against opioid addiction. With continued \u2062collaboration and investment \u2062in\u2063 research, we can hope to achieve\u200c safer, more effective pain management practices and, ultimately, save lives.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA approved AvertD, the first genetic test to determine opioid addiction risk. It is used before a patient&#8217;s initial exposure to opioid painkillers for acute pain treatment, like post-surgery. Notably, James Biden received $600,000<\/p>\n","protected":false},"author":1,"featured_media":2129731,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[538],"tags":[],"class_list":["post-2129730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-washington-examiner"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2129730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2129730"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2129730\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2129731"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2129730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2129730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2129730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}